01:37 , May 5, 2017 |  BC Week In Review  |  Financial News

Aratana proposes $24.4M follow-on

On May 4, animal health company Aratana Therapeutics Inc. (NASDAQ:PETX) proposed to raise $24.4 million through the sale of 5 million shares at $5.25 in a follow-on underwritten by Barclays Capital. Aratana Therapeutics Inc. (NASDAQ:PETX),...
00:57 , Jun 6, 2015 |  BC Extra  |  Company News

Management tracks

Oncology company Halozyme Therapeutics Inc. (NASDAQ:HALO) named Laurie Stelzer CFO, replacing the retiring David Ramsay. Stelzer was SVP of finance for R&D, technical operations and business development at Shire plc (LSE:SHP; NASDAQ:SHPG). Heather Turner resigned...
07:00 , Oct 6, 2014 |  BioCentury  |  Finance

4Q14 Financial Markets Preview: 'Perfect world' - for now

Even as the major biotech indices creep toward new all-time highs, buysiders are hard-pressed to identify any major risks that could cause a downturn in the fourth quarter. At the same time, there are few...
07:00 , Sep 22, 2014 |  BC Week In Review  |  Financial News

Aratana completes follow-on

Aratana Therapeutics Inc. (NASDAQ:PETX), Kansas City, Kan.   Business: Veterinary   Date completed: 2014-09-17   Type: Follow-on   Raised: $47.9 million   Shares: 5.2 million   Price: $9.25   Shares after offering: 34.6 million  ...
07:00 , Jul 28, 2014 |  BC Week In Review  |  Financial News

Aratana financial update

Aratana Therapeutics Inc. (NASDAQ:PETX), Kansas City, Kan.   Business: Veterinary   Date announced: 2014-07-15   Note: Aratana filed a shelf registration covering up to $100 million of its securities. The company, which closed at $12.45...
07:00 , Apr 7, 2014 |  BioCentury  |  Finance

2Q14 Financial Markets Preview: Minor adjustment

Biotech enters 2Q14 facing its second-largest correction since the beginning of the bull run in 2009. However, buysiders believe the worst of the pullback is in the rearview mirror and expect the equity markets will...
07:00 , Mar 24, 2014 |  BC Week In Review  |  Company News

Advaxis, Aratana deal

Advaxis granted animal health company Aratana exclusive, worldwide rights to develop and commercialize ADXS-cHER2 to treat osteosarcoma in dogs as well as three undisclosed cancer immunotherapy products to treat three other types of animal cancers....
08:00 , Mar 3, 2014 |  BC Week In Review  |  Clinical News

Exparel: Phase III data

Data from 183 patients undergoing total knee arthroplasty in the Phase III portion of a 2-part, double-blind, U.S. Phase II/III trial showed that a single femoral nerve blocking administration of 266 mg Exparel met the...
08:00 , Feb 3, 2014 |  BC Week In Review  |  Financial News

Aratana completes follow-on

Aratana Therapeutics Inc. (NASDAQ:PETX), Kansas City, Kan.   Business: Veterinary   Date completed: 1/29/14   Type: Follow-on   Raised: $97.9 million   Shares: 5.2 million   Price: $19   Shares after offering: 29.2 million  ...
08:00 , Feb 3, 2014 |  BC Week In Review  |  Clinical News

AT-005 regulatory update

Aratana said the U.S. Department of Agriculture (USDA) granted conditional approval for AT-005 to treat T cell lymphoma in dogs. The product is a canine-specific mAb against CD52 . The company plans to launch the...